The global acute graft-versus-host disease market size is estimated to be valued at USD 4.07 Billion in 2025. It is projected to reach a valuation of USD 5.46 Billion by 2032, exhibiting a CAGR of 4.3% throughout the forecast period (2025-2032).  

Acute graft-versus-host disease (aGVHD) is a common complication after stem cell transplantation. Increasing demand for novel targeted therapies and the changing approach of value-based care are expected to drive the market growth. Increasing research on monoclonal antibodies, combined with the rise in grant funding for clinical trials to assess the potential of treatments, can also bolster the market growth.

However, limited accessibility to current treatments and their high costs can hamper the market growth.

Key Market Insights

The acute graft-versus-host disease market is shaped by the emergence of cellular therapies and high potential witnessed in Janus kinase (JAK) inhibitors.

• By drug class, the immunosuppressive agents can account for 8.0% market share in 2025. This is attributed to the need for control of the donor T-cell immune response.
• By distribution channel, the pharmacies segment can account for 12.0% market share in 2025. Pharmacies can provide drugs for combination therapies, a requisite in the treatment of aGVHD. Specialty pharmacies are being established in the U.S. for the storage of drugs for rare diseases. This can make the segment a prime source of revenue for the acute graft-versus-host disease market.
• By route of administration, the intravenous segment can account for the fastest growth in the market in 2025. This can be attributed to the administration of intravenous infusions for the prevention of aGVHD through immunosuppressants.
• By geography, the Asia Pacific region is expected to register a robust growth rate over the forecast period. Factors expected to drive growth include precision immunotherapies and increasing demand for stem cell transplants. The rising number of stem cell donors in Southeast Asia, coupled with the rise in allogeneic transplant programs, can expedite the market growth.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/acute-graft-versus-host-disease-market

Acute Graft-versus-Host Disease Market Report Coverage

Report Coverage	Details
Market Revenue in 2025	USD 4.07 Billion
Estimated Value by 2032	USD 5.46 Billion
Growth Rate	4.3%
Historical Data	2020–2024
Forecast Period	2025–2032
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Drug Type, End User, and Distribution Channel
Geographies Covered	North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa)
Growth Drivers	Rising Awareness of Hypercholesterolemia and Increased Diagnostic Efforts Continuous Innovation in Lipid-lowering Therapies, Particularly PCSK9 Inhibitors
Opportunities	Introduction of Less Frequent Injectable Therapies Such as Lerodalcibep Provides a More Convenient Option Increasing Prevalence of Hypercholesterolemia Creates a Larger Target Market for Upcoming Therapies
Trends	Approval of Novel Drugs in Refractory Patients Allogeneic Hematopoietic Cell Transplantation (allo-HCT)
Restraints & Challenges	High Treatment Costs Limit Access for Patients in Certain Regions Challenges in Patient Adherence to Long-term Therapy, Particularly for Injectable Treatments

Market Dynamics

Therapy for refractory patients is expected to drive the demand in the acute graft-versus-host disease market. The relapse witnessed in aGVHD-affected patients and the use of immunosuppressive therapy for aGVHD treatment are expected to drive demand for alternative therapies. This is exemplified by the results of Xervyteg (MaaT013) in clinical trials conducted by MaaT Pharma on November 03, 2025.

Investigational therapies centering around fecal microbiota transplantation and mesenchymal stem cells are likely to show high promise in treatments. The need for the development of a drug for steroid-resistant aGVHD is crucial for patients after stem cell transplants. On March 05, 2024, Cynata Therapeutics commenced patient enrollment for CYP-001, a stem cell technology. It has gained approval for clinical trials in Turkey, the U.S., and Australia. The recent approval for clinical trials in Turkey, the U.S., and Australia can drive the development of future drugs.

Market Opportunity: Biomarker-driven Design for aGVHD Treatment

The use of biomarkers, such as carnitines, lipids, and fatty acids, for the measurement of severity or non-relapse mortality (NRM) can be a prime opportunity in the acute graft-versus-host disease market. They can help clinicians in assessing the risk and long-term outcomes of treatments. For instance, the Mount Sinai Acute GVHD International Consortium (MAGIC) biomarker algorithm, used in providing accurate treatments to patients, is a prime instance.

Market Challenge: Stem Cell Transplants Causing Mortality Rates

While stem cell transplantation remains a curative approach for aGVHD, it remains a major cause of mortality in most cases. The rise of allogeneic transplants and complications arising from post-transplantations can negatively impact the market.

Analyst’s View

• The immunosuppressants segment is anticipated to witness immense growth during the forecast period. The rise of steroid-resistant aGVHD can drive the demand in the segment.
• Key players are investing in clinical trials for the development and production of orphan drugs in the U.S. and the European Union.

Recent Developments

ReAlta Life Sciences, Inc. was granted the Orphan Drug designation for RLS-0071 (pegtarazimod) by the European Medicines Agency (EMA) on August 21, 2025. The drug has the potential to modulate neutrophil and inflammation caused by the primary line of treatment.

Competitor Insights

• Novartis AG
• Humanigen
• medac GmbH
• Incyte Corporation
• Equillium Inc
• CSL Limited
• Cynata Therapeutics Limited
• Bristol-Myers Squibb
• MaaT Pharma
• Merck & Co. Inc
• Mesoblast
• Ironwood Pharmaceuticals

Market Segmentation

• By Drug Class
• Corticosteroids
• Immunosuppressants
• Kinase Inhibitor
• Mesenchymal Stem Cells
• Monoclonal Antibody
• By Distribution Channel
• Hospital Pharmacies
• Pharmacies
• Online Pharmacies
• Retail Pharmacies
• By Route of Administration
• Oral
• Topical
• Intravenous

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa